Reported 1 day ago
Novartis has bolstered its pharmaceutical stockpiles in the U.S. to cope with potential tariffs from President Trump, as CEO Vas Narasimhan stated in a recent interview. Although pharmaceuticals are currently exempt from a imposed 39% tariff, the industry is closely monitoring ongoing investigations that may affect import duties. Narasimhan mentioned plans for significant investments and local production to mitigate any future tariffs, while awaiting clarity from the government regarding the outcome of tariff investigations.
Source: YAHOO